Literature DB >> 15938619

Analysis of active site residues of botulinum neurotoxin E by mutational, functional, and structural studies: Glu335Gln is an apoenzyme.

Rakhi Agarwal1, Thomas Binz, Subramanyam Swaminathan.   

Abstract

Clostridial neurotoxins comprising the seven serotypes of botulinum neurotoxins and tetanus neurotoxin are the most potent toxins known to humans. Their potency coupled with their specificity and selectivity underscores the importance in understanding their mechanism of action in order to develop a strategy for designing counter measures against them. To develop an effective vaccine against the toxin, it is imperative to achieve an inactive form of the protein which preserves the overall conformation and immunogenicity. Inactive mutants can be achieved either by targeting active site residues or by modifying the surface charges farther away from the active site. The latter affects the long-range forces such as electrostatic potentials in a subtle way without disturbing the structural integrity of the toxin causing some drastic changes in the activity/environment. Here we report structural and biochemical analysis on several mutations on Clostridium botulinum neurotoxin type E light chain with at least two producing dramatic effects: Glu335Gln causes the toxin to transform into a persistent apoenzyme devoid of zinc, and Tyr350Ala has no hydrolytic activity. The structural analysis of several mutants has led to a better understanding of the catalytic mechanism of this family of proteins. The residues forming the S1' subsite have been identified by comparing this structure with a thermolysin-inhibitor complex structure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15938619     DOI: 10.1021/bi050253a

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

2.  SNAP-25 substrate peptide (residues 180-183) binds to but bypasses cleavage by catalytically active Clostridium botulinum neurotoxin E.

Authors:  Rakhi Agarwal; Subramanyam Swaminathan
Journal:  J Biol Chem       Date:  2008-07-25       Impact factor: 5.157

3.  Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

4.  Inhibition of catalytic activities of botulinum neurotoxin light chains of serotypes A, B and E by acetate, sulfate and calcium.

Authors:  Rahman M Mizanur; John Gorbet; S Swaminathan; S Ashraf Ahmed
Journal:  Int J Biochem Mol Biol       Date:  2012-09-25

5.  Tetanus neurotoxin utilizes two sequential membrane interactions for channel formation.

Authors:  Joshua R Burns; Michael R Baldwin
Journal:  J Biol Chem       Date:  2014-06-27       Impact factor: 5.157

6.  Substrate recognition mechanism of VAMP/synaptobrevin-cleaving clostridial neurotoxins.

Authors:  Stefan Sikorra; Tina Henke; Thierry Galli; Thomas Binz
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

Review 7.  Clinical uses of botulinum neurotoxins: current indications, limitations and future developments.

Authors:  Sheng Chen
Journal:  Toxins (Basel)       Date:  2012-10-19       Impact factor: 4.546

8.  Comparative membrane channel size and activity of botulinum neurotoxins A and E.

Authors:  Sweta Parikh; Bal Ram Singh
Journal:  Protein J       Date:  2007-01       Impact factor: 4.000

Review 9.  Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering.

Authors:  Thomas Binz; Stefan Sikorra; Stefan Mahrhold
Journal:  Toxins (Basel)       Date:  2010-04-13       Impact factor: 4.546

Review 10.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.